Lessons from Recent Advances in Ischemic Stroke Management and Targeting Kv2.1 for Neuroprotection
Achieving neuroprotection in ischemic stroke patients has been a multidecade medical challenge. Numerous clinical trials were discontinued in futility and many were terminated in response to deleterious treatment effects. Recently, however, several positive reports have generated the much-needed exc...
Main Authors: | Chung-Yang Yeh, Anthony J. Schulien, Bradley J. Molyneaux, Elias Aizenman |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/17/6107 |
Similar Items
-
Nerinetide Reduces Early Infarct Growth Among Stroke Patients Undergoing EVT Without Intravenous Alteplase
by: Nathaniel B. Rex, et al.
Published: (2024-03-01) -
Neuroprotective strategies for acute ischemic stroke: recent progress and future perspectives
by: Oh Young Bang
Published: (2017-09-01) -
Recent advances in nanomedicines for the treatment of ischemic stroke
by: Chao Li, et al.
Published: (2021-07-01) -
The association between gene polymorphisms in voltage-gated potassium channels Kv2.1 and Kv4.2 and susceptibility to autism spectrum disorder
by: Zehui Liu, et al.
Published: (2023-01-01) -
Multiphase adjuvant neuroprotection: A novel paradigm for improving acute ischemic stroke outcomes
by: Wenbo Zhao, et al.
Published: (2020-01-01)